The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs.

Bendicksen, Liam; Kesselheim, Aaron S; Rome, Benjamin N

Bendicksen, Liam; Kesselheim, Aaron S; Rome, Benjamin N.

Bendicksen L; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Kesselheim AS; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Rome BN; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Electronic address: brome@bwh.harvard.edu.

Chest ; 162(2): 433-435, 2022 08.

Article in English | MEDLINE | ID: covidwho-2031192

Subject(s)

Drug Approval; Vasopressins; Drug Industry; Humans; United States; United States Food and Drug Administration

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vasopressins / Drug Approval Limits: Humans Country/Region as subject: North America Language: English Journal: Chest Year: 2022 Document Type: Article Affiliation country: J.chest.2022.02.048

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google